Taysha Gene Therapies, Inc. (TSHA) Operating cash flow 2020–2025
Taysha Gene Therapies, Inc. (TSHA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$93.1MFY2025 · since FY2020: -$30.7M → -$93.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$93.1M | -14.6% |
| FY2024 | -$81.2M | -11.2% |
| FY2023 | -$73.0M | +17.4% |
| FY2022 | -$88.4M | +24.5% |
| FY2021 | -$117.0M | -280.9% |
| FY2020 | -$30.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice